Loss of DNA ligase IV prevents recognition of DNA by double-strand break repair proteins XRCC4 and XLF by Jayaram, Sumithra et al.
Published online 9 September 2008 Nucleic Acids Research, 2008, Vol. 36, No. 18 5773–5786
doi:10.1093/nar/gkn552
Loss of DNA ligase IV prevents recognition of





3 and Les A. Hanakahi
1,*
1Department of Biochemistry and Molecular Biology,
2Department of Molecular Microbiology and
Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
and
3International Graduate School of Arts and Sciences, Yokohama City University, 22-2 Seto, Kanazawa-ku,
Yokohama 236-0027, Japan
Received July 23, 2008; Accepted August 12, 2008
ABSTRACT
The repair of DNA double-strand breaks by nonho-
mologous end-joining (NHEJ) is essential for main-
tenance of genomic integrity and cell viability.
Central to the molecular mechanism of NHEJ is
DNA ligase IV/XRCC4/XLF complex, which rejoins
the DNA. During adenovirus (Ad5) infection, ligase
IV is targeted for degradation in a process that
requires expression of the viral E1B 55k and E4
34k proteins while XRCC4 and XLF protein levels
remain unchanged. We show that in Ad5-infected
cells, loss of ligase IV is accompanied by loss of
DNA binding by XRCC4. Expression of E1B 55k
and E4 34k was sufficient to cause loss of ligase
IV and loss of XRCC4 DNA binding. Using ligase IV
mutant human cell lines, we determined that the
absence of ligase IV, and not expression of viral
proteins, coincided with inhibition of DNA binding
by XRCC4. In ligase IV mutant human cell lines,
DNA binding by XLF was also inhibited. Expression
of both wild-type and adenylation-mutant ligase IV
in ligase IV-deficient cells restored DNA binding
by XRCC4. These data suggest that the intrinsic
DNA-binding activities of XRCC4 and XLF may be
subject to regulation and are down regulated in
human cells that lack ligase IV.
INTRODUCTION
DNA double strand breaks (DSBs) occur in mammalian
chromosomal DNA as a result of normal cellular pro-
cesses like immunoglobulin gene rearrangement and also
as a result of environmental insults such as exposure to
ionizing radiation. Unrepaired or inappropriately repaired
DSBs may cause chromosomal aberrations, which can
result in tumorigenesis. DNA DSBs may be repaired by
nonhomologous end-joining (NHEJ) or by homologous
recombination. NHEJ is a homology-independent process
used for the repair of DSBs during G0, G1 and early
S phases of the cell cycle and can be divided into three
steps: (i) DSB detection—where exposed termini of
double-stranded DNA (dsDNA) are detected and the
repair pathway is initiated; (ii) NHEJ signal transduction
and ampliﬁcation—where the presence of a DSB is sig-
naled to the ligation apparatus; and (iii) synapsis, proces-
sing and ligation—where the exposed DNA ends are
brought into close proximity, modiﬁed to create ligatable
ends and covalently re-joined.
In mammals, the ligation step of NHEJ is catalyzed by
the ATP-dependent DNA ligase IV (ligase IV), which has
been shown to form a functional complex with the DNA-
binding proteins XRCC4 and XLF (1–7). Recent ﬁndings
have demonstrated that the XRCC4 homodimer lies at the
center of the ligase IV/XRCC4/XLF complex and directly
contacts both ligase IV and XLF (8,9). In addition to the
ligase IV/XRCC4/XLF complex, three other mammalian
proteins directly participate in NHEJ. The Ku70/80 het-
erodimer (Ku) and the DNA-dependent protein kinase
catalytic subunit (DNA-PKcs) comprise the heterotri-
meric DNA-dependent protein kinase (DNA-PK), which
is required for NHEJ in vivo and in vitro (10,11). In addi-
tion to these six core factors, the Artemis protein has been
shown to act as a substrate for DNA-PK and is important
for both V(D)J recombination and genomic stability
(12,13).
Much is known about mammalian NHEJ, yet the
molecular mechanism driving this important biological
process, in particular the roles of XRCC4 and XLF,
remains unclear. The crystal structures of both proteins
reveal N-terminal globular head domains with C-terminal
coiled-coil stalks that mediate homo-dimerization
(8,14,15). Recent studies have shown that the N-terminal
globular head domains of XRCC4 and XLF interact
*To whom correspondence should be addressed. Tel: +1 443 287 2515; Fax: +1 410 955 2926; Email: lhanakah@jhsph.edu
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.directly (16), leaving the C-terminal coiled-coil domain of
XRCC4 free for interaction with ligase IV. While the for-
mation of a ligase IV/XRCC4 complex is necessary for
stable expression and function of ligase IV (2), residues
at the extreme N-terminus of XRCC4 that are required
for its intrinsic DNA-binding activity are dispensable for
stimulation of ligase IV in vitro (3,4,17). Interestingly,
while N-terminally truncated DNA-binding mutants
of XRCC4 are able to stimulate ligase IV in vitro, they
are unable to participate in NHEJ in vivo (3,4,17).
These observations suggest that the intrinsic DNA-bind-
ing activity of XRCC4 plays an important, yet uncharac-
terized, role in NHEJ in vivo. Because investigation of
virus–host interactions frequently illuminates the mechan-
ics of host cell processes, we are using adenoviral infection
to study DSB repair by NHEJ in mammalian cells.
Speciﬁcally, we are using adenovirus infection to study
DNA substrate recognition by the ligase IV/XRCC4/
XLF complex.
Wild-type human adenovirus type 5 (Ad5) encodes
early proteins that inhibit NHEJ on a variety of substrates
in infected cells (18–21). Previous work has revealed that a
55-kD protein encoded by adenovirus early region E1B
(E1B 55k) and a 34-kD protein encoded by the open read-
ing frame 6 of early region 4 (E4orf6; E4 34k) (19,20). E1B
55k and E4 34k act in concert with host proteins to form a
virus-speciﬁc E3 ubiquitin ligase that targets several host
proteins in infected cells, including p53, Mre11 and ligase
IV for proteasome-mediated degradation (19,22–24).
Degradation of these proteins inhibits a DNA damage
response otherwise induced by adenovirus infection, inhib-
its p53-dependent apoptosis and prevents NHEJ-mediated
end-to-end concatenation of intracellular viral DNA
molecules (18,19,22–24). In addition to the E1B 55k/E4
34k ubiquitin ligase mechanism of NHEJ inhibition,
there exists a second pathway capable of preventing end-
to-end ligation of the viral genome that requires only the
expression of an 11-kD protein product that is encoded by
the open reading frame 3 of E4 region (E4orf3; E4 11k)
(19). While the expression of either E1B 55k/E4 34k com-
plex or E4 11k can prevent end-joining of the viral
genome, expression of E4 11k does not inhibit other
forms of NHEJ in vivo and fails to inhibit NHEJ in vitro
(25). The distinct eﬀect of E4 11k on adenoviral
genome concatenation is most likely due to inactivation
of Mre11 (26), which is required for genome concatena-
tion (19).
In this communication, we show that E1B 55k/E4 34k-
dependent degradation of ligase IV is accompanied by the
unexpected loss of DNA binding by XRCC4. Direct
assessment of the role of ligase IV in DNA substrate
recognition by XRCC4 and XLF revealed that in
mutant cells lacking functional ligase IV, XRCC4 and
XLF fail to bind DNA. We found that while DNA bind-
ing by XRCC4 required the ligase IV polypeptide, binding
occurred irrespective of the adenylation state of ligase IV.
Finally, we determined that while XLF binds the globular
head of XRCC4, which is responsible for XRCC4 DNA
binding, formation of an XRCC4/XLF complex does not
inhibit DNA recognition by these factors.
MATERIALS AND METHODS
Cell culture, viral infections and DNA transfection
Large-scale infections. HeLa cells (0.5l) were grown in
suspension to 10
6cells/ml in Joklik’s MEM with 5%
Newborn Calf Serum, 100units/ml penicillin and 100mg/
ml streptomycin (PenStrep), collected by centrifugation,
resuspened in fresh medium at 5 10
6cells/ml in a spinner
ﬂask and virus was added to 10pfu/cell. Virus was allowed
to adsorb for 2h at 378C with gentle agitation. Cells were
collected by centrifugation, resuspended at 10
6cells/ml in
fresh culture medium and grown for 16h postinfection
(HPI). For small-scale infections, 293 cells were cultured
as monolayers in EMEM supplemented with 10% fetal
bovine serum (FBS) and PenStrep in 25cm
2 ﬂasks.
Small-scale infections in HeLa cells were done by cultur-
ing cells as a monolayer in 35mm dishes supplemented
with DMEM containing 10% FBS and Penstrep. For
virus infection, culture media is aspirated and replaced
with fresh FBS free media and the virus was added at
10pfu/cell. Virus was allowed to adsorb for 2h after
which FBS free media is aspirated and replaced with
fresh media containing 10% FBS. The infection was car-
ried out for 18h. 2V6.11 cells (27) were cultured as mono-
layers in EMEM with 10% FBS and PenStrep in 25cm
2
ﬂasks. LB2304 cells were cultured in RPMI 1640 with
15% FBS, PenStrep and 10% sodium pyruvate in 10-cm
dishes. NBS3703 cells cultured in DMEM with 15% FBS,
PenStrep and 10% sodium pyruvate in 10-cm dishes.
Nalm-6 cells were cultured in RPMI 1640 with 10%
FBS with 50mM b-mercaptoethanol in 25cm
2 ﬂasks.
Nalm-6 cell transfections were carried out by electropora-
tion of 8 10
6cells/ml with 20mg of plasmid DNA at
250V with ﬁve pulses each at 2ms with 1s between
pulses. The electroporated cells were added back to the
25cm
2 ﬂasks and grown for 60h in RPMI 1640 with
10% FBS with 50mM b-mercaptoethanol. pcDNA 3.1
plasmids expressing WT Ligase IV-his and R278H-his
were a generous gift from Penny Jeggo (University of
Sussex, UK).
Preparation of extracts
Suspension grown HeLa cells were harvested by centrifu-
gation and whole cell extract (WCE) was prepared essen-
tially as described by Baumann and West (28). Mini-whole
cell extract (mWCEs) were prepared as previously
described (25). Brieﬂy, monolayer cells were harvested
using a cell scraper, washed twice in phosphate-buﬀered
saline (PBS), snap frozen on dry ice and stored at –808C.
Frozen cell pellets were resuspended in 70–90ml of hypo-
tonic lysis buﬀer [10mM Tris (pH 8.0), 1mM EDTA as
described in (28)], incubated on ice for 20min then subject
to vigorous vortexing for 30s. Nuclei were collected by
gentle centrifugation (1300g, 2min, and room tempera-
ture) and the supernatant was reserved. Nuclei were resus-
pended in 35–45ml of nuclear extract buﬀer (25mM Tris
pH 8.0, 0.33M KCl, 1.5mM EDTA) and incubated on ice
for 20min. The reserved cytoplasmic extract was added
back to the nuclei, cell debris was removed by centrifuga-
tion (16500g, 10min, 48C) and the resulting supernatant
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determined by Bradford (BioRad, California, USA) ana-
lysis prior to storage at –808C.
Immunoprecipitaiton and adenylation assays
For co-immunoprecipitations (co-IP) HeLa cells were
washed twice in PBS and lyzed in NP40 lysis buﬀer
[50mM Tris HCl (pH 8.0), 150mM NaCl, 2mM EDTA,
10% glycerol, 1mM DTT and 1% NP40] for 20min at
48C. Cellular debris was removed by centrifugation
(13000g,4 8C, 10min) and the protein concentration of
the resulting supernatant was determined by Bradford
(BioRad) analysis. An extract of 200mg was treated with
1:200 dilution of mouse polyclonal XRCC4 (Novus bio-
logicals, Colorado, USA) for 2h at 48C with gentle end-
over-end mixing. For control IP, FBS (1:200 dilution) was
added to 200mg of the extracts for 2h at 48C with gentle
end-over-end mixing. After 2h, 30ml of protein A sephar-
ose beads (Amersham) was added after being washed
three times in NP40 lysis buﬀer. The mixture is then incu-
bated for 1h at 48C with gentle end-over-end mixing. The
samples were washed 5–8 times in NP40 lysis buﬀer to
remove unbound proteins, proteins were resolved by
SDS–PAGE, subject to western transfer and individual
proteins were detected as indicated. Adenylation assays
were performed as previously described (29).
InvitroNHEJ,dsDNA–cellulosefractionationandantibodies
Assays for in vitro NHEJ were carried out as described in
(11,28). Brieﬂy, reactions (10ml) were carried out in
50mM HEPES pH 8.0, 40mM KOAc, 0.5mM
Mg(OAc)2, 1mM ATP, 1mM DTT, 0.1mg/ml BSA,
contained 2–4ml (10–40mg) of WCE and Hind III-linear-
ized 50-
32P-labeled pBluescribe DNA (10ng). Incubation
was for 2h at 378C.
32P-labeled DNA products were
deproteinized and analyzed by electrophoresis through
0.6% agarose gels followed by autoradiography. For
dsDNA–cellulose fractionation, 20ml of a 50% native
DNA cellulose (Sigma, Montana, USA) slurry was
added directly to 130ml of 0.4mg/ml extract, incubated
for 3h at room temperature with turning, collected by
centrifugation, washed with 3 1ml in HEK buﬀer
[20mM HEPES (pH 7.6), 0.1M KOAc, 0.5mM
EDTA] and resuspended in 2  protein sample buﬀer.
Samples were heated to 1008C for 5min, resolved by
SDS–PAGE and subject to western transfer. In quality
control experiments,
32P end-labeled DNA incubated
with extract for up to 4h at 378C showed no signiﬁcant
degradation (data not shown), and so we believe that
DNA used in our DNA-binding experiment remains
intact during the room temperature DNA-binding reac-
tion as described above. XRCC4 was detected with anti-
XRCC4 rabbit polyclonal antibodies (Serotec, North
Carolina, USA, 1:3000). DNA-PKcs was detected with
anti-DNA-PKcs rabbit polyclonal antibodies (Serotec,
1:2000). Ligase IV was detected with anti-ligase IV
rabbit polyclonal antibody (Serotec, 1:1000). E4 34k was
detected using anti-E4 34k rabbit polyclonal antibodies
against C-terminal peptide (27,30) (1:1000). E1B 55kDa
was detected using 2A6 mouse monoclonal antibody
(1:5000) (31). Ku70 was detected using anti-Ku70 rabbit
polyclonal antibody (1:1000) (32). Ku80 was detected
using anti-Ku80 mouse monoclonal antibody (Serotec,
1:3000). V5-tagged XLF was detected using anti-V5
mouse monoclonal antibody (Serotec, 1:1000). WT his6-
ligase IV and his6-R278H were detected using anti-his6
antibodies (GE, USA, 1:3000). Anti-XRCC4 antibodies
(Serotec) were used to neutralize NHEJ in vitro at a
1:250 dilution. XLF antibodies were a generous gift
from S. Jackson (Cambridge, UK).
Phosphocellulose, gel filtration and
phosphopeptide-capturechromatography
HeLa WCEs were prepared and fractionated step-wise
over phosphocellulose in L buﬀer [20mM Tris (pH 8.0),
0.5mM EDTA, 10% glycerol, 1mM DTT] with step-
elutions at 0.25M, 0.6M and 1M KCl as previously
described (11,28). Superdex-200 gel ﬁltration was per-
formed according to manufacturer’s speciﬁcations in
25mM Tris pH 8.0, 0.5M KCl and 0.5mM EDTA.
An extract of 0.5mg was fractionated and 0.6ml frac-
tions were collected. Molecular weight standards
were purchased from GE. Phosphopeptide capture was
carried out using the PhophoProtein Puriﬁcation Kit
(Qiagen, California, USA) according to manufacturer’s
instructions.
Cloning,coexpression and purification of
GST-XLF and XRCC4-his6
To generate C-terminally his6-tagged XRCC4-his6: the
XRCC4 cDNA was removed as an NcoI/EcoRV fragment
from pcDNA3.1 XRCC4-V5-His [a generous gift from D.
Durocher (33)]. pET28a(+) was digested with EcoRI, the
30-overhang was Klenow ﬁlled and resulting DNA was
cleaved with NcoI. Both the vector, pET28a(+) and
insert, XRCC4, were gel puriﬁed, ligated, transformed
into DH5a and plated on LB-Kan. Clones were selected
by PCR ampliﬁcation of the XRCC4 cDNA, positive
clones were subject to direct DNA sequence analysis,
found to be free of mutations, and transformed into
Escherichia coli strain Rosetta 2 (Novagen, New Jersey,
USA) to conﬁrm production of XRCC4-his6. The result-
ing clone is called pET28a(+)XRCC4-his6. To produce
N-terminally GST-tagged GST-XLF: pEX-4T-XLF, a
generous gift from S. Jackson (Cambridge, UK), was sub-
ject to direct sequence analysis and found to be free of
mutations. For protein expression, plasmids were trans-
formed into Cam-resistant E. coli strain Rosetta 2.
pET28a(+)XRCC4-his6 was plated on LB-Kan, Cam
and pEX-4T-XLF plated on LB-Amp, Cam. For coex-
pression of XRCC4-his6 and GST-XLF, plasmids were
co-transformed into Cam-resistant E. coli strain Rosetta
2 and plated on LB-Amp, Kan, Cam. Cells were grown at
378C in LB broth with the appropriate antibiotics to
OD600=1.0, induced with 0.25mM IPTG and then cul-
tured at 378C for an additional 4.5h before being har-
vested by centrifugation and stored at –808C. For
tandem aﬃnity puriﬁcation of XRCC4-his6 and GST-
XLF, Ni-NTA (Qiagen) aﬃnity chromatography was car-
ried out according to manufacturer’s instructions.
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0.15M NaCl] with 10mM imidazole with 50mg/ml lyso-
zyme ncubated on ice for 15min and PMSF was added to
1mM ﬁnal concentration. The resulting lysate was soni-
cated (3 20s at 30% power) and cellular debris was
removed by centrifugation (25000g,4 8C, 30min). A
50% Ni-NTA slurry of 0.8ml was added to 10ml of
lysate ( 100mg) and the sample was bound in batch at
48C for 60min with gentle end-over-end turning before
being poured into a column. The lysate was allowed to
ﬂow through and the retained Ni-NTA resin was washed
with 4ml of Ni-buﬀer with 10mM imidazole and eluted in
Ni-buﬀer with 0.5M imidazole. Peak fractions were iden-
tiﬁed by Bradford analysis, pooled, 4M NaCl was added
to bring the ﬁnal NaCl concentration to 0.3M and the
resulting sample was applied to a 0.4ml glutathione
sepharose (GE) column prewashed with G-buﬀer
(50mM Tris pH 8.0, 0.3M NaCl, 5mM EDTA, 1mM
DTT, 1mM PMSF, 0.2mM benzamidine). The sample
was allowed to ﬂow through the glutathione sepharose
column, captured and re-applied, after which the column
was washed in G-buﬀer eluted with 40mM free glu-
tathione. Peak fractions were identiﬁed by Bradford ana-
lysis, pooled and dialyzed into 20mM Tris pH 8.0, 50mM
NaCl, 5% glycerol, 0.5mM EDTA and 1mM DTT.
To purify XRCC4-his6 alone, Ni-NTA aﬃnity chromato-
graphy was carried out as described above. To purify GST-
XLFalone,glutathionesepharoseaﬃnitychromatography
was carried out as described above. All protein concentra-
tion was determined by Bradford analysis and samples
were stored at –808C.
RESULTS
Inhibition ofDNA bindingby XRCC4 accompanied
loss of ligaseIV andinhibition ofNHEJ in
adenovirus-infected cells
Previous studies have shown that NHEJ is inhibited in
adenovirus-infected cells and that this is caused by
the targeted degradation of ligase IV during infection
(18–21,24,27). While the levels of other NHEJ factors
remained unchanged during adenoviral infection
(Supplementary Figure S1C) (24), phosphocellulose frac-
tionation of extracts prepared from Ad5-infected HeLa
cells revealed a change in the chemistry of XRCC4.
Fractionation of extracts prepared from uninfected cells
has shown that XRCC4 binds to phosphocellulose
(Figure 1A) (28). In fractionating extracts prepared from
Ad5-infected cells, we found that XRCC4 did not bind
phosphocellulose, but quantitatively ﬂowed through a
Figure 1. XRCC4 DNA binding is inhibited in an E4 34k-dependent fashion in adenovirus-infected cells. (A) Partitioning of XRCC4 on phospho-
cellulose was altered by Ad5 infection. HeLa cells were either Mock- or Ad5-infected, extracts were prepared and subject to phosphocellulose
chromatography. Load (L), ﬂow-through (FT) 0.25, 0.6 and 1M KCl washes were resolved by SDS–PAGE, subject to western transfer and probed
for the presence of XRCC4. (B) Puriﬁed XRCC4 binds dsDNA cellulose. Recombinant XRCC4-his6 was expressed and puriﬁed as described in
Materials and methods section and subject to dsDNA–cellulose fractionation at 1.4 pM XRCC4-his6. The input fraction (Input), DNA-bound
fraction (Bound) and the sample following removal of DNA-bound XRCC4-his6 (Unbound) were resolved by SDS–PAGE, western transferred and
probed for the presence of XRCC4. (C) mWCE (50mg) prepared from 293 cells that were Mock- or Ad5-infected 293 cells were subject to dsDNA–
cellulose fractionation. The input extract (Input), DNA-bound species (Bound) and the extract following removal of DNA-binding proteins
(Unbound) were resolved by SDS–PAGE, subject to western transfer and probed for the presence of XRCC4 or DNA-PKcs, as indicated. (D)
mWCE of 50mg prepared from HeLa cells that were Mock-, Ad5-, dl1011-, dl1013-, dl1014- or dl1015-infected were treated as in (B) and probed for
the presence of XRCC4. Expression of E3 34k, E1B 55k and Ligase IV is indicated. All extracts were prepared 18 HPI.
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NHEJ in Ad5-infected cells is undoubted due to virus-
directed degradation of ligase IV, phosphocellulose frac-
tionation of extracts from Ad5-infected cells showed
that the chemistry of XRCC4 had changed, which may
reﬂect changes of the entire ligase IV/XRCC4/XLF
complex.
Like many of the factors involved in NHEJ, XRCC4
possesses an intrinsic DNA-binding activity and recog-
nizes dsDNA in a sequence-independent manner (4,34).
Because phosphate recognition is important in retention
of a protein on phosphocellulose and in DNA binding, we
chose to examine the DNA-binding activity of XRCC4 to
determine if the observed lack of XRCC4 retention on
phosphocellulose following adenovirus infection was the
result of a change in the biologically relevant activity of
XRCC4. Puriﬁed, recombinant his6-tagged XRCC4 was
used as a reference and we determined the concentration
of endogenous XRCC4 in mWCE to be  1.4pM (data
not shown). While XRCC4 is thought to have a relatively
weak DNA-binding activity, we used native dsDNA cel-
lulose fractionation to study the intrinsic DNA-binding
activity of puriﬁed, recombinant XRCC4 at 1.4pM.
Western blot analysis was then used to assess the presence
of XRCC4 in the input fraction (input), the DNA-bound
fraction and the fraction following capture of DNA-bind-
ing proteins (unbound). We found that the recombinant
XRCC4 bound dsDNA cellulose and could only be
detected in the DNA-bound fraction (Figure 1B). These
data show that DNA binding by XRCC4 can be examined
using dsDNA cellulose fractionation.
To determine if adenoviral infection had any aﬀect on
DNA binding by XRCC4, we examined extracts prepared
from mock- and Ad5-infected 293 cells and found that
XRCC4 was present in similar amounts, despite viral
infection. In extracts prepared from mock-infected 293
cells, we found XRCC4 to be capable of binding
dsDNA and present in the DNA-bound fraction, which
we had anticipated (Figure 1C). When dsDNA-cellulose
fractionation was carried out with extracts prepared from
Ad5-infected 293 cells, XRCC4 was not found in the
DNA-bound fraction (Figure 1C). The lack of XRCC4
in the DNA-bound fraction was not due to degradation
of XRCC4 during the DNA-binding reaction, as full-
length XRCC4 was found in the unbound fraction
(Figure 1C). These data suggest that adenoviral infection
and expression of adenovirus early proteins directly or
indirectly prevented DNA recognition by XRCC4.
In control experiments, we examined the eﬀect of adeno-
virus infection on DNA binding by other NHEJ factors.
DNA-PKcs was present in the input and DNA-bound
fractions of mock- and Ad5-infected cells and was not
detected in unbound fraction (Figure 1C). Similar results
were obtained for the Ku heterodimer, which was found
in the input and DNA-bound fractions of both mock-
and Ad5-infected cells, but was not observed in unbound
fractions (data not shown). These control experiments
show that the dsDNA cellulose used in these experi-
ments was available for recognition by DNA-binding
proteins. In particular, the exposed DNA ends,
which represent the physiological substrate for NHEJ
factors, were accessible. These data indicate that inhibition
of DNA binding was unique to XRCC4 and not caused
by a general mechanism that aﬀected all DNA-binding
proteins.
Targeted degradation of ligase IV requires expression of
viral proteins E1B 55K and E4 34k. To investigate the role
of adenoviral protein E4 34k in the observed loss of DNA
binding by XRCC4 in adenovirus-infected cells, we exam-
ined XRCC4 DNA recognition in extracts prepared from
HeLa cells that had been infected with various early
region 4 (E4)-deletion mutants. HeLa cells were infected
with E4-deletion mutants shown in Supplementary
Figure S1A, extracts were prepared and western blot ana-
lysis was used to assess the expression of E1B 55k and E4
34k (Supplementary Figure S1B). Native DNA cellulose
was then used to capture DNA-binding proteins and wes-
tern blot analysis to detect XRCC4 in the input extract,
the DNA-bound fraction and in the extract following
removal of DNA-binding proteins (unbound). Figure 1D
shows that in extracts prepared from HeLa cells infected
with E4-deletion mutants that did not express E4 34k,
XRCC4 was detected in the DNA-bound fraction in
amounts that were comparable to that observed with
mock-infected cells. In extracts prepared from HeLa
cells infected with wild-type Ad5 or with E4-deletion
mutant dl1013, which retains E4 34k expression, XRCC4
was not detectable in the DNA-bound fraction but was
found in the unbound fraction. Western blot analysis
showed that loss of XRCC4 DNA-binding activity was
coincident with expression of adenoviral proteins E1B
55k and E4 34k (Supplementary Figure S1B) and degra-
dation of ligase IV (Supplementary Figure S1C). Taken
together, data presented in Figure 1 and Supplementary
Figure S1 show that inhibition of DNA recognition by
XRCC4, like degradation of ligase IV, is dependent
upon adenoviral infection and expression of both the
E1B 55k and E4 34k proteins.
XRCC4 remains in large complexes in
adenovirus-infected cells
Loss of DNA binding by XRCC4 in adenovirus-infected
cells may reﬂect gross alteration of XRCC4 (i.e. changes in
protein structure or protein–protein interaction) incurred
during poly-ubiquinylation and degradation of the ligase
IV that is bound to XRCC4. In Ad5-infected cells, the
relocalization of Mre11 to cytoplasmic aggresomes is
thought to interfere with the normal function of the
Mre11-Rad50-Nbs1 (MRN) complex (26). XRCC4 is a
nuclear factor and using in situ immunoﬂuorescence we
found that, unlike the MRN complex, XRCC4 remained
nuclear in Ad5-infected cells (data not shown).
Having determined that XRCC4 was not re-localized in
Ad5-infected cells, we went on to determine if interactions
with other NHEJ factors were aﬀected by adenoviral
infection. First, we carried out gel ﬁltration analysis on
extracts prepared from mock- or Ad5-infected HeLa
cells, then used western blot analysis to identify
XRCC4-containing fractions to determine the average
size of XRCC4-containing complexes. The average size
of XRCC4-containing complexes was reduced in
Nucleic Acids Research, 2008, Vol. 36, No. 18 5777extracts prepared from Ad5-infected cells when compared
with extracts prepared from mock-infected cells
(Supplementary Figure 2A). While the loss of ligase IV
might account for the observed decrease in the average
size of XRCC4-containing complexes, these complexes
are still relatively large ( 200–350kDa), suggesting the
continued participation of XRCC4 in multi-protein com-
plexes. In addition to recognition of ligase IV that partic-
ipates in a large protein complex, anti-ligase IV antibodies
directed against the C-terminal domain of ligase IV also
recognized a 100kDa species that migrated near 100kDa
on gel ﬁltration. While antibody recognition makes it rea-
sonable to conclude that this species that was not
degraded during Ad5 infection is an interesting sub-
population of ligase IV, we cannot rule out the unlikely
possibility that this species may be DNA ligase I or III.
Our ﬁndings show that during adenoviral infection,
XRCC4 protein levels, localization and participation in
multi-protein complexes remained unchanged, which sug-
gest that the XRCC4 protein was not grossly altered
during adenoviral infection.
XRCC4 is known to interact directly with the DNA-
PKcs, and it is thought that this interaction is important
for NHEJ (35). We used co-IP assays to determine if this
protein–protein interaction was maintained or lost in Ad5-
infected cells. Immunoprecipitation (IP) of XRCC4 was
carried out using extracts prepared from mock- or Ad5-
infected HeLa cells and western blot analysis was used to
determine if DNA-PKcs was co-immunoprecipitated with
XRCC4. XRCC4 is associated with DNA-PKcs in mock-
infected cells, and this interaction was unaﬀected by ade-
noviral infection (Supplementary Figure 2B). Our ﬁndings
show that XRCC4 levels and localization remained
unchanged and the ability to interact with DNA-PKcs
was not altered, which suggest that the XRCC4
protein was not signiﬁcantly altered during adenoviral
infection.
E1B55k and E434k are sufficient forinhibition of
NHEJ andloss of XRCC4 DNA binding
Data presented thus far show that E1B 55k and E4 34k
expression are required to inhibit DNA recognition by
XRCC4 and NHEJ in vitro. To determine if E1B 55k
and E4 34k are suﬃcient to inhibit DNA binding by
XRCC4, we examined the eﬀect of expression of E1B
55k and E4 34k in the 2V6.11 cell line that had been engi-
neered to carry E4 34k under Ponesterone A (Pon A)
inducible control (27). 2V6.11 cells were derived from
293 cells, which constitutively express proteins from ade-
novirus early region 1 (E1), including E1B 55k, E1a 289R
and 243R and E1B 19K (36,37). We found that, as pre-
viously described (27), the E1B 55k protein can be detected
in extracts prepared from 2V6.11 cells and that Pon A
treatment resulted in expression of E4 34k (Figure 2A).
As shown in Figure 2A, extracts prepared from 2V6.11
cells that had been induced to express E4 34k
showed reduced NHEJ activity when compared with
extracts prepared from untreated or mock-induced
(DMSO) controls. In control experiments, Pon A treat-
ment of the parental 293 cells had no eﬀect on in vitro
NHEJ (data not shown). Western blot analysis showed
that in 2V6.11 cells where E4 34k expression was induced,
ligase IV was undetectable while levels of the other NHEJ
factors were unchanged (Figure 2B). This is consistent
with previous observations that of adenoviral gene
products, E1B 55k and E4 34k are suﬃcient to ablate
ligase IV, which presumably explains the reduction of
NHEJ in 2V6.11 extracts in vitro.
To determine if DNA binding by XRCC4 was inhibited
by the expression of E1B 55k and E4 34k, we compared
XRCC4 DNA binding in extracts prepared from Pon
A-induced and mock-induced 2V6.11 cells. As shown in
Figure 2C, while XRCC4 was clearly observed in the
DNA-bound fraction of extracts prepared from mock-
induced 2V6.11 cells, with extracts prepared from Pon
Figure 2. Expression of E1B 55k and E4 34k are suﬃcient for inhibition of NHEJ and loss of XRCC4 DNA binding. mWCEs were prepared from
2V6.11 cells that were untreated, DMSO or Pon A (2mg/ml) treated for 48h. (A) Expression of E1B 55k and E4 34k resulted in inhibition of in vitro
NHEJ. (top) In vitro NHEJ assays were carried out using 40mg of mWCE. ‘-’ denotes the lane where no mWCE was added during NHEJ reaction.
mWCE of 50mg was resolved on SDS–PAGE, subject to western transfer and probed for the presence of E4 34k or E1B 55k as noted. (B) Levels of
NHEJ factors were assayed in 50mg of mWCE prepared from DMSO- or Pon A-treated 2V6.11 cells. Extracts were resolved on SDS–PAGE, western
transferred and proteins were detected as indicated. (C) Loss of XRCC4 DNA binding in extracts prepared from cells expressing E1B 55k and E4
34k. mWCE of 50mg prepared from DMSO- or Pon A-treated 2V6.11 cells was subject to dsDNA–cellulose fractionation. The input extract (Input),
DNA-bound species (Bound) and the extract following removal of DNA-binding proteins (Unbound) were resolved by SDS–PAGE, subject to
western transfer and probed for the presence of XRCC4. Expression of E4 34k, E1B 55k and Ligase IV is indicated.
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XRCC4 on dsDNA–cellulose resin DNA binding by
XRCC4 was greatly reduced. Thus, expression of E1B
55k and E4 34k and loss of ligase IV in 2V6.11 cells is
coincident with loss of DNA binding by XRCC4. We note
that these data do not rule out the possibility that another
E1 protein participates in inhibiting DNA binding by
XRCC4. Although ligase IV was undetectable in extracts
prepared from Pon A-induced cells, low levels of in vitro
NHEJ activity and XRCC4 DNA binding were detected.
We attribute these observations to remaining ligase IV at
levels below the limit of western blot detection.
Loss ofligase IV, notviral protein expression,
correlated withloss of DNA binding by XRCC4
Thus far, our ﬁndings show that loss of ligase IV, through
poly-ubiquitinylation and proteasome-mediated degrada-
tion, and the expression of viral proteins, in particular
E1B 55k and E4 34k, correlate with the observed loss
of DNA binding by XRCC4. To separate the eﬀect(s) of
loss of ligase IV from those of viral protein expression,
we assayed for DNA binding by XRCC4 in extracts pre-
pared from ligase IV-mutant human cell lines. In control
DNA-binding experiments with extracts prepared from
untreated 2V6.11 cells, both wild-type ligase IV and
XRCC4 were found in the DNA-bound fraction
(Figure 3A). Because this series of experiments focused
on the substrate-recognition properties of the ligase
IV/XRCC4/XLF complex, we also probed for the pre-
sence of XLF in the DNA-bound fraction. As shown in
Figure 3A, XLF, like XRCC4 and wild-type ligase IV, was
detected in the input and DNA-bound fractions of
extracts prepared from untreated 2V6.11 cells. These
data show that all three members of the ligase
IV/XRCC4/XLF complex are retained on native DNA
cellulose, which may reﬂect the intrinsic DNA-binding
activities of the individual factors, or the DNA-binding
activity of the complex as a whole.
To investigate the role of ligase IV in DNA recognition
by XRCC4 and XLF, we used cell lines NBS3703 and
LB2304 that bear LIG4 nonsense mutations and conse-
quently do not contain enough ligase IV to be observable
by western blot (38,39). In NBS3703 cell extracts,
we found that XRCC4 and XLF were detectable in
the input extract and in the extracts following depletion
of DNA-binding proteins (unbound fraction), but
were not found in the DNA-bound fraction (Figure 3).
Control experiments that tested for DNA binding by Ku
(Figure 3) and DNA-PKcs (data not shown) demon-
strated that the dsDNA used in these experiments was
accessible and suitable for recognition by DNA-binding
proteins. Similarly, we observed that in extracts prepared
from LB2304 cells, XRCC4 was present but was not
retained by the DNA cellulose, while Ku was detected in
the DNA-bound fraction (Figure 3). To rule out the pos-
sibility that factors that inhibit DNA binding by the ligase
IV/XRCC4/XLF complex may be present in extracts pre-
pared from ligase IV mutant cells, we carried out mixing
experiments in which extracts prepared from control
untreated 2V6.11 or 293 cells were combined with native
or heat-treated extracts prepared from LB2304 or
NBS3703 cells, then assayed for DNA binding by
XRCC4. Under these conditions, we observed no reduc-
tion in retention of XRCC4 or ligase IV, presumably con-
tributed by the 2V6.11 extract, by dsDNA cellulose resin
(data not shown).
Data presented in Figure 3 show that in extracts pre-
pared from cell lines that contain ligase IV nonsense muta-
tions, XRCC4 and XLF were not retained by dsDNA
cellulose, which indicates that the intrinsic DNA-binding
activities associated with these factors have been inhibited.
These ﬁndings rule out the participation of adenoviral
proteins in inhibition of XRCC4 DNA binding and put
forward the hypothesis that loss of ligase IV results in the
observed loss of DNA binding by the remaining compo-
nents of the ligase IV/XRCC4/XLF complex. To test this
hypothesis, we examined retention of XRCC4 and XLF
on native DNA cellulose in extracts prepared from Nalm-
6 cells in which both copies of the LIG4 gene had been
knocked out [Nalm-6 LIG4
 / , (40)]. Control dsDNA–
cellulose fractionation experiments carried out with wild-
type Nalm-6 cells (Figure 4A, right) showed that ligase IV,
XRCC4 and Ku were detected in the input extract and
DNA-bound fractions, but were not observed in extracts
following depletion of DNA-binding proteins (Figure 4A,
right). To assess DNA binding by XLF, V5-tagged XLF
Figure 3. DNA binding by XRCC4 requires ligase IV. DNA binding by NHEJ factors in mWCEs prepared from untreated (control) 2V6.11 (A),
NBS3703 (B) and LB2303 cells (C). 50mg of mWCE was subject to dsDNA–cellulose fractionation. The input extract (Input), DNA-bound species
(Bound) and the extract following removal of DNA-binding proteins (Unbound) were resolved by SDS–PAGE, subject to western transfer and
individual factors were detected as indicated.
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Western blot analysis using anti-V5 antibodies showed
that V5-XLF was detected in the input extract and
the DNA-bound fraction, but not in the unbound
fraction (Figure 4A). In contrast, we found that in extracts
prepared from LIG4
 /  Nalm-6 cells (Figure 4A, left), the
ligase IV protein was not detectable and while both
XRCC4 and V5-XLF were detected in the input extract
and in the extract following depletion of DNA-binding
proteins, neither were detected in the DNA-bound frac-
tion (Figure 4A). DNA accessibility was conﬁrmed by the
presence of Ku in the DNA-bound fraction, which sug-
gests that occlusion of the DNA by other DNA-binding
factors is not responsible for the lack of XRCC4 and
V5-XLF retention by dsDNA cellulose.
Thus far, our ﬁndings are consistent with the hypothesis
that, in human cells, the ligase IV polypeptide is required
for DNA binding by XRCC4 and XLF. To directly test
this hypothesis, we used electroporation for high-eﬃciency
transient expression of his-tagged wild-type ligase IV
in wild-type and LIG4
 /  Nalm-6 cells. As shown in
Figure 4B, the his6-ligase IV cDNA was expressed
in wild-type Nalm-6 cells and expression of this cDNA
did not alter DNA binding by XRCC4. Importantly, we
found that when his6-ligase IV was expressed in LIG4
 / 
Nalm-6 cells, XRCC4 was observed in the DNA-bound
fraction (Figure 4B).
Ligase IV has been shown to interact with Ku, which is
thought to recruit the ligase IV/XRCC4/XLF complex to
exposed DNA ends (41–43). In the presence of ligase IV,
binding of the ligase IV/XRCC4/XLF complex to DNA is
facilitated by ligase IV/Ku interactions. In the absence of
ligase IV, binding of abundant Ku to the dsDNA cellulose
might prevent binding and recovery of XRCC4. To test
this possibility, puriﬁed, recombinant XRCC4-his6 was
added to extracts prepared from wild-type or LIG4
 / 
Nalm-6 cells at a ﬁnal concentration of 1.4 pM, to
match the concentration of endogenous XRCC4 in the
extracts. The recombinant XRCC4-his6 was pre-incubated
with the Nalm-6 extracts in the absence of dsDNA cellu-
lose for an hour, after which DNA–cellulose fractionation
was carried out to isolate DNA-binding proteins. Anti-
his6 antibodies were used to detect the recombinant
XRCC4-his6, apart from the endogenous XRCC4. As
shown in Figure 4C, the recombinant XRCC4-his6
bound the DNA in the presence of both wild-type and
LIG4
 /  Nalm-6 extracts. These data show that the
dsDNA cellulose used in these experiments is accessible
to binding by XRCC4 and that lack of DNA binding by
XRCC4 in LIG4
 /  Nalm-6 extracts was not caused by
Figure 4. Loss of ligase IV protein correlates with inhibition of DNA binding by XRCC4. (A) DNA binding by NHEJ factors in extracts prepared
from Nalm-6 cells. mWCE (50mg) prepared from ligase IV-deﬁcient (Nalm-6 LIG4
 / ) and wild-type (Nalm-6 LIG4
wt) cells was subject to dsDNA–
cellulose fractionation. The input extract (Input), DNA-bound species (Bound) and the extract following removal of DNA-binding proteins
(Unbound) were resolved by SDS–PAGE, subject to western transfer and individual factors were detected as indicated. For detection of XLF
DNA binding: cells were transiently transfected with V5-tagged XLF, extracts were prepared 60h after transfection, DNA-binding proteins were
isolated and V5-XLF was detected using anti-V5 antibodies. (B) Expression of wild-type ligase IV restored DNA binding by XRCC4 in ligase
IV-deﬁcient cells. pcDNA3.1 expressing his-tagged wild-type ligase IV (his6-ligase IV) was transiently transfected into Nalm-6 LIG4
 /  and Nalm-6
LIG4
wt cells. Extracts were prepared 60h after transfection and 50mg of extract were fractionated on dsDNA–cellulose. XRCC4 was detected as
described in (A) and ectopically expressed his6-Ligase IV was detected using anti-his6 antibodies. ‘-’ denotes empty lane. (C) Recombinant his6-tagged
XRCC4 binds DNA in the presence of Nalm-6 cell extracts. Recombinant XRCC4-his6 was expressed and puriﬁed as described in Materials and
methods section, then added to 100mg of extract prepared from Nalm-6 LIG4
 /  or Nalm-6 LIG4
wt cells to a ﬁnal concentration of 1.4pM. Samples
were incubated in the absence of DNA for 1h, after which the samples were subject to dsDNA–cellulose fractionation. Recombinant XRCC4-his6
was detected using anti-his6 antibodies. (D) Nalm-6 cells (LIG4
 /  and LIG4
wt) were cultured in the presence of wortmannin (20mM) or the vehicle
(DMSO) for 24h. mWCEs were prepared, samples were subject to dsDNA–cellulose fractionation and XRCC4 was detected as described in (A).
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Additionally, these data indicate that soluble factors are
not likely to cause the observed inhibition of XRCC4
DNA recognition and implicate posttranslational modiﬁ-
cation and formation of stable protein–protein complexes
as likely mechanisms for regulation of XRCC4 DNA
binding.
Phosphorylation of recombinant XRCC4 by DNA-PK
in vitro has been shown to inhibit XRCC4 DNA binding
(4). DNA-PKcs phosphorylation sites were subsequently
mapped to the C-terminal 100 amino acids of XRCC4
(44). Because the ligase IV binding site of XRCC4 lies
within the C-terminal coiled-coil domain of XRCC4, it
is plausible that these DNA-PK phosphorylation sites
are made accessible when ligase IV is absent and that
phosphorylation of XRCC4 results in inhibition of
DNA binding by XRCC4. To test this hypothesis, we
captured phosphopeptides from LIG4
 /  Nalm-6 cell
extracts and used western blot analysis to conﬁrm that
XRCC4 is a phosphoprotein in the absence of ligase IV
(data not shown). We then treated wild-type and LIG4
 / 
Nalm-6 cells with wortmannin (20mM) or the vehicle
(DMSO) for 24h, after which time extracts were prepared
and DNA–cellulose fractionation was carried out to
isolate DNA-binding proteins. As shown in Figure 4D,
wortmannin treatment had no eﬀect on the DNA-binding
activity of XRCC4 in extracts prepared from wild-type
Nalm-6 cells. XRCC4 in extracts prepared from
LIG4
 /  Nalm-6 cells remained unable to associate with
DNA, despite wortmannin treatment. These data indicate
that while XRCC4 is phosphorylated in the absence of
ligase IV, phosphorylation dependent upon PI3K-related
PK activity is not required for ablation of XRCC4 DNA
binding activity.
Formation of theligase-adenylate isnot requiredfor DNA
binding by theligase IV/XRCC4/XLF complex
During ligation, an ATP-dependent ligase ﬁrst reacts with
ATP to form a ligase-adenylate. Some ligases, such as the
Chlorella virus ligase, require formation of the ligase-
adenylate for DNA recognition (45,46). Other ligases are
capable of DNA recognition regardless of adenylation
status. Recombinant ligase IV/XRCC4 exhibits a weak
DNA-binding activity on short DNA substrates and it
has been reported that formation of the ligase IV-adeny-
late is necessary for Ku-mediated binding of recombinant
ligase IV/XRCC4 to short DNA substrates (47,48). Along
these lines, we found that XRCC4 in cell line 180BRM,
which expresses a mutant ligase IV with reduced ability to
form the ligase IV-adenylate, fails to bind DNA (data not
shown). These data suggest that formation of the ligase
IV-adenylate may be required for DNA binding by the
ligase IV/XRCC4/XCLF complex.
To directly assess the role of ligase IV-adenylate
formation on binding to DNA cellulose, we chemically
removed the adenosine from the ligase IV-adenylate,
then assayed for DNA binding by the deadenylated
ligase IV. To do this, we treated puriﬁed recombinant
ligase IV/XRCC4 complex with inorganic pyrophosphate
to disrupt preformed ligase-adenylates. Adenylation of
untreated ligase IV/XRCC4 complex with
32PaATP con-
ﬁrmed that, as previously demonstrated (2,48), recombi-
nant ligase IV was already in the ligase-adenylate form
and could not be adenylated (data not shown).
Adenylation of recombinant ligase IV following pyro-
phosphate treatment conﬁrmed that ligase IV could
form a
32P-labeled ligase IV-adenylate (data not shown).
To determine what fraction of ligase IV-adenylate is
disrupted by pyrophosphate treatment, we treated the
32P-labeled ligase IV-adenylate with pyrophosphate and
were unable to detect
32P-labeled ligase IV-adenylate
remaining in the sample (data not shown). These data
indicate that treatment of ligase IV with pyrophosphate
can disrupt the preformed ligase IV-adenylate. Following
ligase-adenylate disruption, the pyrophosphate was
removed from the reaction and native DNA cellulose
was used to isolate DNA-binding proteins. We found
that DNA binding by puriﬁed recombinant ligase
IV/XRCC4 was unaﬀected by pyrophosphate treatment,
which indicated that the formation of the ligase-adenylate
was not required for DNA binding by this complex
(Figure 5A). In similar experiments, extracts prepared
from untreated 2V6.11 cells were treated with pyropho-
sphate to disrupt preformed ligase-adenylates. As
observed for puriﬁed recombinant proteins, ligase IV
and XRCC4 were detected in the input extracts and in
the DNA-bound fractions, but were not detected in
extracts following removal of DNA-binding proteins
(Figure 5B). Thus, in the context of these treated human
cell extracts, ligase-adenylates were not required for DNA
binding.
In parallel experiments, we transiently expressed a
mutant form of ligase IV (ligase IV
R278H), which is
severely impaired for formation of the ligase IV-adenylate
(29), in Nalm-6 cells and assessed DNA binding by
XRCC4. To conﬁrm the adenylation defect of his6-ligase
IV
R278H, extracts prepared from LIG4
 /  Nalm-6 cells
expressing his6-ligase IV
R278H were treated with pyropho-
sphate, or left untreated, and ligase IV immunoprecipi-
tates were subject to adenylation with
32PaATP
(Figure 5C). We found that, as previously described
(29), neither untreated nor pyrophosphate-treated his6-
ligase IV
R278H was capable of forming a his6-ligase
IV
R278H-adenylate. In contrast, control reactions with
extracts prepared from LIG4
 /  Nalm-6 cells expressing
wild-type his6-ligase IV showed that his6-ligase IV could
be adenylated, but only after pyrophosphate treatment to
disrupt the preformed his6-ligase IV-adenylate
(Figure 5C). Detection of ligase IV showed that his6-
ligase IV and his6-ligase IV
R278H were expressed at com-
parable levels and that treatment with NaPPi and subse-
quent removal of NaPPi did not aﬀect the amount of
ligase IV present in the sample. DNA–cellulose fractiona-
tion of extracts prepared from wild-type NALM-6 cells
expressing his6-ligase IV
R278H showed XRCC4 and his6-
ligase IV
R278H in the input and DNA-bound fractions
(Figure 5D, right). When the his6-ligase IV
R278H protein
was expressed in LIG4
 /  Nalm-6 cells, XRCC4 and his6-
ligase IV
R278H were detected in the DNA-bound fraction
(Figure 5D, left). These data show that restoration of the
ligase IV polypeptide was suﬃcient to restore DNA
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nylate was not required for binding of long DNA sub-
strates. Ligase IV in 180BRM cells has been describe as
unstable (29), and we attribute our original observation
that XRCC4 fails to recognize DNA in extracts prepared
from 180BRM cells to the instability of ligase IV in these
cells, and not to the inability of ligase IV in these cells to
form the ligase IV-adenylate.
The XRCC4/XLF complex binds DNA
Investigation of the mode of interaction between XRCC4
and XLF has revealed that XLF binds to the N-terminal
globular-head domain of XRCC4, which is also the DNA-
binding domain (3,4,16,17). This observation suggests that
binding of XRCC4 by XLF may inhibit DNA recogni-
tion by XRCC4. Consistent with this possibility, XLF
co-immunoprecipitates (co-IP) with XRCC4 in extracts
prepared from wild-type and LIG4
 /  Nalm-6 cells
(Figure 6A). V5-tagged XLF was transiently expressed
in wild-type and LIG4
 /  Nalm-6 cells and XRCC4
were immunoprecipitated (IP) to capture XRCC4-con-
taining complexes. To rule out the possibility of DNA-
mediated interactions, the XRCC4 IP was also carried
out in the presence of ethidium bromide (EtBR), which
can disrupt nonspeciﬁc protein–DNA interactions. As
shown in Figure 6A, western blot analysis using anti-V5
antibodies shows that XLF is present in the XRCC4
co-IP, even in the presence of EtBR. These data show
that in the absence of ligase IV, XLF binds XRCC4,
and may interfere with XRCC4 DNA binding.
To directly test the hypothesis that formation of an
XRCC4/XLF complex inhibits DNA binding by
XRCC4 and XLF, we coexpressed C-terminally his-
tagged XRCC4 (XRCC4-his6) and N-terminally
GST-tagged XLF (GST-XLF) in E. coli, used Ni-NTA
and glutathione sepharose aﬃnity chromatography in
tandem to isolate complexes that contain XRCC4-his6
and GST-XLF, then assayed for DNA binding by these
hetero-oligomeric complexes. Figure 6B shows the crude
lysate and the Ni-NTA peak elution fraction, which was
highly enriched for XRCC4-his6. Subsequent glutathione
sepharose aﬃnity chromatography captured those com-
plexes also containing GST-XLF, while unbound
XRCC4-his6 ﬂowed through the column. The peak glu-
tathione sepharose fraction shows two bands of equal
intensity with molecular weights corresponding to those
of XRCC4-his6 and GST-XLF. Co-IP and western blot
analysis were used to conﬁrm puriﬁcation of an XRCC4-
his6/GST-XLF complex (Figure 6B). Using native DNA
cellulose, we found that both XRCC4-his6 and GST-XLF
puriﬁed in this fashion were able to bind DNA (Figure 6D
and E), which indicates that formation of an XRCC4/
XLF complex does not inhibit the intrinsic DNA-binding
activities of XRCC4 and XLF.
Figure 5. DNA binding by ligase IV/XRCC4 does not require ligase IV adenylation. (A) Disruption of the ligase IV-adenylate did not aﬀect DNA
binding by recombinant ligase IV/XRCC4 complex. Puriﬁed, recombinant ligase IV/XRCC4 complex (10mg) was treated with 5mM sodium
pyrophosphate (NaPPi) for 15min to disrupt the ligase–adenylate complex. Treatment was followed by removal of pyrophosphate and both
NaPPi-treated and untreated samples were subject to dsDNA–cellulose fractionation. Input extract (Input), DNA-bound species (Bound) and the
extract following removal of DNA-binding proteins (Unbound) were resolved by SDS–PAGE, western transferred and probed for the presence of
Ligase IV and XRCC4 as indicated. Bottom panel was assembled from lanes from a single western blot. ‘-’ denotes empty lane. (B) Disruption of the
ligase IV-adenylate did not aﬀect DNA binding by ligase IV/XRCC4 in human cell extracts. An extract prepared from untreated 2V6.11 cells (50mg)
was treated with 5mM NaPPi for 15min, after which the sample was treated as described in (A). (C) Ligase IV
R278H does not form the ligase
IV-adenylate. pcDNA3.1 expressing wild-type or R278H mutant (his6-R278H) ligase IV was transiently transfected into Nalm-6 LIG4
 /  cells.
mWCEs were prepared 60h after transfection, treated with 5mM NaPPi for 15min, after which pyrophosphate was removed. Ectopically
expressed Ligase IV was co-immunoprecipitated from extracts using anti-XRCC4 antibodies and in vitro adenylated with
32PaATP as previously
described (29).
32P-labeled ligase IV adenylate was detected by autoradiography (
32P) and ligase IV was detected by western blot. (D) Expression of
ligase IV
R278H restored DNA binding by XRCC4 in ligase IV-deﬁcient cells. pcDNA3.1 expressing his-tagged ligase IV
R278H (his6-R278H) was
transiently transfected into Nalm-6 LIG4
 /  and Nalm-6 LIG4
wt cells, extracts were prepared 60h after transfection and 50mg of mWCE were
subject to dsDNA–cellulose fractionation. XRCC4 was detected as described in (A) and ectopically his6-ligase IV
R278H was detected using anti-his6
antibodies.
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The details of cellular processes may be explored through
the study of virus–host interactions. By using human ade-
novirus as a tool to study mammalian NHEJ, we have
uncovered a novel aspect of NHEJ: in human cells,
DNA recognition by XRCC4 and XLF requires the
ligase IV polypeptide.
Expression of adenoviral E1B 55k and E4 34k proteins
is required for proteasome-meditated degradation of
ligase IV (24), which is the most likely cause of the
observed inhibition of NHEJ in adenovirus-infected cells
(19,21–25). We have observed that expression of E1B 55k
and E4 34k also results in inhibition of DNA binding by
XRCC4. Correlation of the loss of DNA binding by
XRCC4 and XLF and degradation of ligase IV led us to
take a closer look at the DNA-binding properties of
XRCC4 in human cells that lacked ligase IV for other
reasons. Using ligase IV-deﬁcient mutants, we found
that the lack of ligase IV correlated with loss of XRCC4
binding in uninfected cells, despite the documented intrin-
sic DNA-binding activity of XRCC4 (4). We then exam-
ined the behavior of another DNA-binding protein that
interacts with XRCC4, the XLF protein (6,49). In human
cells expressing defective ligase IV, we found that XLF,
like XRCC4, failed to bind DNA. These data imply
that substrate recognition by XRCC4 and XLF in vivo
requires the participation of ligase IV. Furthermore,
these data suggest the exciting hypothesis that the intrinsic
DNA-binding activity of XRCC4, and possibly that of
XLF, may be subject to regulation and is, in fact, down-
regulated in cells lacking ligase IV.
Inhibition of XRCC4 DNA-binding activity was not
due to degradation of XRCC4, as the absolute amount
of XRCC4 in ligase IV mutant cell lines or in Ad5-infected
cells was comparable to the wild-type and uninfected cells.
Inhibition of XRCC4 DNA binding was not caused by a
general mechanism aﬀecting all DNA-binding proteins
Figure 6. DNA binding by the XRCC4/XLF complex. (A) Co-IP of XRCC4 and XLF from Nalm-6 cells. Cells were transiently transfected with
V5-tagged XLF. Extracts were prepared 60h after transfection and IP with anti-XRCC4 antibodies was used to collect XRCC4-containing complexes
in the presence and absence of EtBr (50mg/ml) to disrupt protein–DNA interactions (IP: X4 and IP: X4 + EtBR). Samples were resolved on
SDS–PAGE, subject to western transfer and ectopically expressed V5-XLF was detected using anti-V5 antibodies. (B) Expression and puriﬁcation of
XRCC4-his6/GST-XLF complex. Escherichia coli strain Rosetta 2 was co-transformed with pET28a(+)XRCC4-his6 (Kan
R) and pEX-4T-XLF
(Amp
R) and protein expression was induced with IPTG for 4.5h at 378C. Crude lysate (L) was subject to tandem Ni-NTA (Ni), glutathione
sepharose (GSH) aﬃnity chromatography. Peak elution fractions are shown. (C) Co-IP of XRCC4-his6 and GST-XLF. Antibodies directed against
XRCC4 (right) or GST (left) were used to IP XRCC4 and GST-XLF, respectively. The input fraction (Input), immunoprecipitated complexes
(IP) and control IPs (C) of 10% were resolved on SDS–PAGE, subject to western transfer and XRCC4 and GST-XLF were detected as indicated.
(D and E) DNA binding by the XRCC4-his6/GST-XLF complex. dsDNA–cellulose fractionation was carried out using glutathione sepharose eluate
(GST-XLF/XRCC4-his6), GST-XLF alone and XRCC4-his6 alone. The input fraction (Input), DNA-bound species (Bound) and the sample
following removal of DNA-binding proteins (Unbound) were resolved on SDS–PAGE, western transferred and XRCC4 and GST-XLF were
detected as indicated. ‘-’ denotes empty lane.
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experiments or competition by DNA of host or viral
genome origin in the extracts) because DNA binding by
DNA-PKcs and Ku were unchanged by Ad5-infection,
expression of a defective ligase IV or ligase IV deﬁciency.
Down-regulation of DNA binding by the XRCC4/XLF
complex when ligase IV is absent would prevent assembly
of unproductive, potentially mutagenic, complexes at
exposed DNA termini. Our observation that XRCC4
and XLF, two intrinsic DNA-binding proteins, paradoxi-
cally fail to associate with DNA when ligase IV is absent
supports this hypothesis. Related observations show
that XRCC4 and XLF fail to associate with damaged
chromatin in the absence of ligase IV (50,51). We found
that when XRCC4 and XLF were coexpressed in E. coli
to form an XRCC4/XLF complex, both proteins retained
DNA-binding activity, which indicates that XRCC4
DNA-binding activity is not regulated through association
with XLF.
Regulation of many biochemical activities is achieved
by protein phosphorylation, and it has been shown that
in vitro phosphorylation of recombinant XRCC4 by
DNA-PK results in the loss of XRCC4 DNA binding
(4). Subsequent mapping and genetic analysis of this phos-
phorylation event revealed that phosphorylation of
XRCC4 by DNA-PK at the sites examined was dispensa-
ble for NHEJ in vivo (44). While these data argue that
phosphorylation of XRCC4 by DNA-PK at these speciﬁc
sites is of limited importance to NHEJ in vivo, they do not
exclude the possibility that other sites of DNA-PK phos-
phorylation may be of biological importance. Using
WCEs, we have observed that phosphorylation of
XRCC4 by DNA-PKcs is coincident with accumulation
of end-joining products in vitro (data not shown). Drouet
et al. (51) have shown that in cells expressing ligase IV,
recruitment of XRCC4 to damaged chromatin requires
DNA-PK and is accompanied by DNA-PK-dependent
phosphorylation of XRCC4. Consistent with this report,
we failed to observe DNA binding by XRCC4 or ligase IV
in extracts prepared from DNA-PKcs-deﬁcient cells (data
not shown). We also found that treatment of wild-type of
LIG4
 /  Nalm-6 cells with wortmannin to inhibit DNA-
PKcs activity had no eﬀect on DNA binding by XRCC4.
Taken together, these observations indicate that the
DNA-PKcs polypeptide plays an important role in assem-
bly of NHEJ factors at exposed DNA termini, but the role
of XRCC4 phosphorylation by DNA-PKcs and the
molecular mechanism of XRCC4 DNA-binding regula-
tion remain unresolved.
Whereas the possibility that DNA-PK may regulate
substrate recognition by XRCC4 is of considerable inter-
est, it is important to note that XRCC4 is also a substrate
for the ubiquitous casein kinase II (CK2), which is
thought to regulate interactions between the ligase IV/
XRCC4-XLF complex and human polynucleotide kinase
(PNK) (33,52). The regulation of DNA recognition by the
ligase IV/XRCC4/XLF complex may require the con-
certed eﬀorts of several PKs is a tantalizing possibility.
Through western blot analysis, we have observed
that XRCC4 from wild-type and LIG4
 /  Nalm-6 cells
have identical mobility on SDS–PAGE. Side-by-side
comparison of XRCC4 in the DNA-bound and unbound
fractions from wild-type and LIG4
 /  Nalm-6 cells,
respectively, also showed no detectable diﬀerence in
XRCC4 mobility (data not shown). These data are con-
sistent with 2D western blot analysis that showed no dif-
ference in the abundance or apparent charge of XRCC4 in
extracts prepared from wild-type and ligase IV-deﬁcient
cells (data not shown). These observations suggest that
XRCC4 carries the same number of phosphates in the
presence and absence of ligase IV, but provides no infor-
mation regarding the speciﬁc residues that are modiﬁed.
It is interesting to note that while all components of
the ligase IV/XRCC4/XLF complex are DNA-binding
proteins, the relative contributions of each factor to the
process of substrate recognition have not been clearly
deﬁned. As previously described, XRCC4N-terminal dele-
tion mutants that fail to bind DNA remain capable of
associating with ligase IV and stimulating ligation
in vitro, suggesting that XRCC4 DNA-binding activity
is, in fact, dispensable for ligase complex function
(3,4,17). While these studies were limited to the ligase
IV/XRCC4 complex, it is plausible that XRCC4 does
not contribute signiﬁcantly to substrate recognition by
the ligase IV/XRCC4/XLF complex in mammalian cells
and that the majority of protein–DNA contacts are
formed by ligase IV. Our data support this hypothesis,
as XRCC4/XLF complexes expressed in mammalian
cells that lack ligase IV do not bind DNA. Further inves-
tigation into the regulation of DNA binding by XRCC4,
and XLF, is expected to yield new insights into mechan-
isms that safeguard genomic stability.
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